4 results
The objective of this randomized, blinded, multicenter, controlled study is to compare the performance of the IBV* Valve System (treatment group) to a control group receiving a sham bronchoscopy procedure without valve placement
To prospectively test for superiority of atogepant 60 mg QD versus placebo for the prevention of migraine in participants with episodic migraine who have previously failed 2 to 4 classes of oral medications for the prophylaxis of migraine
To evaluate the safety and tolerability of treatment with atogepant 60 mg once daily when administered over 156 weeks for the prevention of migraine in participants with Chronic Migraine (CM) or Episodic Migraine (EM).
to test the feasibility of the study protocol for operability, intensity and logistics and to test whether the chosen activities can be measured as expected, in order to provide a guideline for testing maximum aerobic capacity and the metabolic…